2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4443 Operationalization and feasibility of the sickle cell outcomes grading system (SCOGS) using real world data

Tarun Aurora, MD, MSCI, Renee Hodges, BA2, Joseph R Wardell, MPH3, Janna Lipford4, Clifford Takemoto, MD5, Deepa Manwani I, MD6, Nickhill Bhakta7, Jane Hankins, MD,MS8
1 Emory University, Atlanta, GA, United States
2 St. Jude Children's Research Hospital, Memphis, United States
3 St. Jude Children's Research Hospital, Memphis, United States
4 St. Jude Children's Research Hospital, Memphis, United States
5 St. Jude Children's Research Hospital, Memphis, United States
6 St. Jude Children's Research Hospital, Memphis, United States
7 St. Jude Children's Research Hospital, Memphis, United States
8 St. Jude Children's Research Hospital, Memphis, United States

Background

The Sickle Cell Outcomes Grading System (SCOGS) is a novel framework designed to standardize the assessment of disease severity in individuals with sickle cell disease (SCD) across 53 clinical outcomes (Aurora, Lancet Haematology, 2026). SCOGS incorporates graded severity across SCD manifestations and is intended to capture its heterogeneous clinical burden. Following initial publication, evaluation in large, real-world cohorts is needed to determine whether SCOGS-defined outcomes can be operationalized using routinely collected clinical data and to identify areas requiring refinement before broader implementation.

Objective

To evaluate the operationalization and feasibility of applying the system to grade SCOGS-defined outcomes within a large, longitudinal, real-world SCD registry and to characterize patterns of incomplete outcome classification across different complication types.

Methods

We retrospectively applied SCOGS to 1604 individuals with SCD enrolled in the Sickle Cell Clinical Research and Intervention Program (SCCRIP) (Hankins, Pediatr Blood Cancer, 2018), a longitudinal cohort study. SCOGS outcomes were operationalized using available clinical, laboratory, imaging, and other registry data. Each outcome was categorized as completely scored when all information required to apply the SCOGS definition was available and the outcome could be assigned a final grade. Outcomes were partially scored when some components of the grading framework could be applied but classification was limited by discordance among grading components or by missing laboratory or clinical variables. Outcomes were classified as unscored when the target outcome could not be identified within the dataset because the required documentation or diagnostic laboratory data were unavailable. Outcomes were grouped into three subtypes: acute, chronic, and chronic with exacerbation. Analyses focused on the proportion of SCOGS outcomes that could be fully or partially operationalized and on identifying patterns of incomplete classification across complication types.

Results

Of the 53 SCOGS outcomes, 45 were able to be evaluated within the SCCRIP cohort. For 8 patients, no population was defined within the registry. Overall, 19 (36%) outcomes were completely scored, 9 (17%) were partially scored, and 25 (47%) were unscored, including the 8 outcomes for which a definable population was unavailable. Feasibility varied by outcome subtype. Among 23 acute outcomes, 5 (22%) were completely scored, 5 (22%) were partially scored, and 13 (57%) were unscored. Among 24 chronic outcomes, 12 (50%) were completely scored, 4 (17%) were partially scored, and 8 (33%) were unscored. Of the 6 chronic-with-exacerbation outcomes, 2 (33%) were completely scored, while 4 (67%) could not be scored without further chart review.

Incomplete scoring reflected several distinct limitations in real-world data capture. Partial scoring was primarily attributable to discordance among individual components contributing to a single SCOGS grade or to missing laboratory and clinical variables. Outcomes were unscored when the outcome could not be identified in the registry, when documentation required for grading was absent, or when diagnostic laboratory data were unavailable. Outcomes requiring manual chart review, patient-reported data, or composite definitions were less feasible across all outcome subtypes. Chronic outcomes were generally more feasible to operationalize than acute outcomes, likely reflecting greater availability of longitudinal. However, even among chronic outcomes, incomplete data capture limited the ability to apply SCOGS comprehensively.

Conclusion

In a large retrospective, real-world SCD cohort, SCOGS-defined severity classifications could be operationalized but were only partially feasible using existing registry data. Feasibility varied across outcome subtypes and was primarily limited by incomplete capture of clinical, laboratory, imaging, and patient-reported information. These findings support the utility of SCOGS as a standardized framework for multidimensional SCD severity assessment while highlighting the importance of aligning registry data collection with the specific variables required for grading. Future implementation efforts should prioritize standardized capture of non-discrete clinical data, diagnostic laboratory testing, imaging findings, patient-reported outcomes, and the clinical context needed to resolve discordance among grading components.

Tarun Aurora, MD, MSCI: Agios Pharmaceuticals - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony)